https://sputnikglobe.com/20210419/russias-rdif-hualan-biological-bacterin-agree-to-produce-100mln-sputnik-v-doses-in-china-1082668068.html
Russia's RDIF, Hualan Biological Bacterin Agree to Produce 100Mln Sputnik V Doses in China
Russia's RDIF, Hualan Biological Bacterin Agree to Produce 100Mln Sputnik V Doses in China
Sputnik International
MOSCOW (Sputnik) - The Russian Direct Investment Fund (RDIF) announced on Monday that it had reached an agreement with China's Hualan Biological Bacterin to... 19.04.2021, Sputnik International
2021-04-19T08:09+0000
2021-04-19T08:09+0000
2021-04-19T08:09+0000
https://cdn1.img.sputnikglobe.com/img/07e5/03/1f/1082501697_0:72:3385:1976_1920x0_80_0_0_1836b872fa381ab1037f6005231f9f2e.jpg
russia
china
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
2021
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
News
en_EN
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
newsfeed, russia, china, russian direct investment fund (rdif)
newsfeed, russia, china, russian direct investment fund (rdif)
Russia's RDIF, Hualan Biological Bacterin Agree to Produce 100Mln Sputnik V Doses in China
MOSCOW (Sputnik) - The Russian Direct Investment Fund (RDIF) announced on Monday that it had reached an agreement with China's Hualan Biological Bacterin to produce over 100 million doses of Russia's Sputnik V vaccine against COVID-19 per year in China.
"RDIF ... and Hualan Biological Bacterin Inc. (a subsidiary company of one of China’s leading biopharmaceutical producers and the largest influenza vaccine manufacturer, Hualan Biological Engineering Inc.), today have announced the cooperation on production of over 100 million doses per year of the world’s first registered vaccine against coronavirus Sputnik V in China. This amount of the vaccine will be sufficient to vaccinate over 50 million people," RDIF said in a press release.
RDIF CEO Kirill Dmitriev expressed confidence that the cooperation agreement would help "significantly increase the production capacities of Sputnik V" and also praised China as a key partner.
Sputnik V has so far been approved for use in 60 countries worldwide. According to the medical journal The Lancet, the drug has 91.6% efficacy against symptomatic COVID-19.
